for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted “icovamenib” as the United States Adopted Name (USAN) for BMF-219. The suffix ‘-menib ...

Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development ...

Biomea Fusion (BMEA) announced that the World Health Organization, WHO, has approved “icovamenib” as the International Nonproprietary Name, INN, for its lead product candidate BMF-219 ...

Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cellsREDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- ...

for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted "icovamenib" as the United States Adopted Name (USAN) for BMF-219. The suffix '-menib' stands ...